<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1806233821
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Sogroya 5 mg / 1.5ml
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SOMAPACITAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        3.3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1024.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Novo Nordisk Bagsvaerd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Novo Nordisk Bagsvaerd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 4691]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novo nordisk Saudi trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01AC07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sogroya<sup>&reg;</sup> contains the active substance somapacitan: a long acting version of the natural growth hormone produced by the body with a single amino acid substitution. Growth hormone regulates the composition of fat, muscle and bone in adults.</p><p>&nbsp;</p><p>The active substance in Sogroya<sup>&reg;</sup> is made by &#39;recombinant DNA technology&#39;, meaning from cells that have received a gene (DNA) that makes them produce growth hormone. In Sogroya<sup>&reg;</sup>, a small side-chain has been attached to the growth hormone which links Sogroya<sup>&reg;</sup> to the protein (albumin) naturally found in the blood to slow down its removal from the body, allowing the medicine to be given less often.</p><p>&nbsp;</p><p dir="RTL">Sogroya<sup>&reg;</sup> is used to treat growth failure in children and adolescents aged 2.5 years and above if they have no or very low production of growth hormone (growth hormone deficiency) and adults who have growth hormone deficiency.</p><p>Your doctor will evaluate based on your response to Sogroya<sup>&reg;</sup>, if you should continue your treatment with Sogroya<sup>&reg;</sup> a year after starting with this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Sogroya<sup>&reg;</sup></strong><!--[if supportFields]><b><s><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:#0070C0;mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_62fb9a45-dbe4-4c4f-b609-a9aadb80ff99 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></s></b><![endif]--><strong><s>&nbsp;</s></strong><!--[if supportFields]><b><s><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:#0070C0;mso-ansi-language:
EN-GB'><span style='mso-element:field-end'></span></span></s></b><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or the child in your care are allergic to somapacitan or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or the child in your care have a benign or malignant tumour which is growing. You must have completed your anti-tumour treatment before you start your Sogroya<sup>&reg;</sup> treatment. Sogroya<sup>&reg;</sup> must be stopped if the tumour grows.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or the child in your care have recently had open heart surgery or abdominal surgery or multiple accidental injury, severe breathing problems or similar condition.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for children and adolescents who have stopped growing because of closure of the growth plates (closed epiphyses) meaning that you or the child in your care have been told by your doctor that your bones have stopped growing.</p><p>&nbsp;</p><p>If you are not sure talk to your doctor, pharmacist or nurse.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d834dced-4db4-4bb0-9487-c2bb5a1a4b53 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>Warnings and precautions</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0f887bdb-07eb-49e2-be65-4af698a44bdd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-ansi-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Talk to your doctor, pharmacist or nurse before using Sogroya<sup>&reg;</sup> if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or the child in your care have ever had any kind of tumour</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or the child in your care have high blood sugar (hyperglycaemia) as your blood sugar may need to be checked regularly and the dose of your diabetes medicine may need to be adjusted</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or the child in your care have a replacement therapy with corticosteroids, because you have been told your body does not produce enough (adrenocortical insufficiency). Speak to your doctor, as your dose may need regular adjustment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or the child in your care have severe headaches, eyesight problems, nausea, or vomiting as these could be symptoms of increased pressure in the brain (benign intracranial hypertension) as your treatment may need to be stopped</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or the child in your care have thyroid problems, your thyroid hormones need to be checked regularly and your dose of thyroid hormone may need to be adjusted</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are a female taking oral contraception or hormonal replacement therapy with oestrogen, your dose of Sogroya<sup>&reg;</sup> may need to be higher. If you stop using oral oestrogen, your dose of somapacitan may need to be reduced. Your doctor may recommend you to change the route of oestrogen administration (e.g transdermal, vaginal) or use another form of contraception.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or the child in your care are seriously ill (for example, complications following open heart surgery, abdominal surgery, accidental trauma, acute respiratory failure, or similar conditions). If you are about to have, or have had, a major operation, or go into hospital for the above reasons, tell your doctor and remind the other doctors you are seeing that you use growth hormone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or the child in your care develop a severe stomach ache during treatment with Sogroya<sup>&reg;</sup> as this could be a symptom of inflammation of the pancreas seen in treatments with other growth hormone products.</p><p>&nbsp;</p><p dir="RTL">Skin changes at the injection site</p><p dir="RTL">The injection site of Sogroya<sup>&reg;</sup> should be rotated to prevent changes to the fatty tissue under the skin, such as skin thickening, skin shrinking or lumps under the skin. Change the place of injection on your body from one week to the next.</p><p dir="RTL">&nbsp;</p><p>Antibodies</p><p>You are not expected to get antibodies against somapacitan. However, only very rarely your child may get antibodies. If your Sogroya<sup>&reg;</sup> treatment does not work, your doctor may test you for antibodies to somapacitan.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and </strong><strong>Sogroya<sup>&reg;</sup></strong><!--[if supportFields]><b><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_7de7cfdc-157d-40b2-8b78-d938a7d31d30 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Tell your doctor or pharmacist if you or the child in your care are using, have recently used or might use any other medicines.</p><p>In particular, tell your doctor if you or the child in your care are taking or have recently taken any of the following medicines.</p><p>This is because your doctor may have to adjust the doses of your medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids such as hydrocortisone, dexamethasone and prednisolone</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oestrogen as part of oral contraception or hormonal replacement therapy with oestrogen</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Male sex hormones (androgen medicines) such as testosterone</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gonadotropin medicines (gonad stimulating hormones such as luteinising hormone and follicle-stimulating hormone) which stimulate the production of sex hormones</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insulin or other diabetes medicines</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thyroid hormone medicines such as levothyroxine</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to treat epilepsy or fits (seizures) &ndash; such as carbamazepine</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cyclosporine (immunosuppressive drug) &ndash; a medicine to suppress your immune system.</p><p>&nbsp;</p><p><strong>Pregnancy</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8c999c1a-85bd-4da5-a64e-c6b077175f74 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are able to get pregnant, you should not use Sogroya<sup>&reg;</sup> unless you are also using reliable contraception. This is because it is not known if it could harm your unborn child. If you become pregnant while you are using Sogroya<sup>&reg;</sup>, speak to your doctor immediately. If you wish to become pregnant, discuss it with your doctor, as you may need to stop using the medicine.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is not known whether Sogroya<sup>&reg;</sup> can pass into breast milk. Tell your doctor if you are breast-feeding or plan to do so. Your doctor will then help you decide whether to stop breast-feeding, or whether to stop taking Sogroya<sup>&reg;</sup>, considering the benefit of breast-feeding to the baby and the benefit of Sogroya<sup>&reg;</sup> to the mother.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Sogroya<sup>&reg;</sup> does not affect your ability to drive and use machines.</p><p>&nbsp;</p><p><strong>Sodium content</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Sogroya<sup>&reg;</sup> is given as an injection under the skin (subcutaneous injection) from a pre-filled pen. You can give the injection yourself. Your doctor or nurse will tell you the right dose and show you how to give the injection when you or the child in your care start treatment.</p><p>&nbsp;</p><p><strong>When to use Sogroya<sup>&reg;</sup></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You or the child in your care should use Sogroya<sup>&reg;</sup> once a week on the same day each week if possible.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can give yourself the injection at any time of the day.</p><p>&nbsp;</p><p dir="RTL">If you or the child in your care are changing from another weekly growth hormone therapy to Sogroya<sup>&reg;</sup>, you are advised to continue injecting on the same week day.</p><p dir="RTL">If you or the child in your care are changing from daily growth hormone therapy to Sogroya<sup>&reg;</sup> choose the preferred day for the weekly dose and inject the last dose of daily treatment the day before (or at least 8 hours before) injecting the first dose of Sogroya<sup>&reg;</sup></p><p dir="RTL">Changing from another type or brand of growth hormone should be done by your doctor.</p><p dir="RTL">&nbsp;</p><p dir="RTL">If it is not possible for you or the child in your care to inject Sogroya<sup>&reg;</sup> on your usual week day, you can inject Sogroya<sup>&reg;</sup> up to 2 days before or 3 days after your scheduled dosing day. The next dose you can inject as usual the following week.</p><p>&nbsp;</p><p>If necessary you can change the day of your weekly injection of Sogroya<sup>&reg;</sup> as long as it has been at least 4 days since you had your last injection of it. After selecting a new dosing day, continue giving yourself the injection on that day each week.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_10be858d-ec7b-47ee-9481-e8a80744c8f0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>How long you will need treatment for</strong><!--[if supportFields]><b><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ec634a3e-8bfd-44c1-8f50-08cd5ea293a5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>You may need Sogroya<sup>&reg;</sup> for as long as your body does not produce enough growth hormone.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_3c31dba7-06f0-46a2-8ac8-8bf5e91b1843 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care are using Sogroya<sup>&reg;</sup> for growth failure you will continue using Sogroya<sup>&reg;</sup> until you stop growing.<!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_86d303b1-ec5f-41e4-9861-6bbf3a58f09d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care still lack growth hormone after you stop growing, you may need to continue using Sogroya<sup>&reg;</sup> into adulthood.<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;color:black;mso-themecolor:text1;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c34a8f8d-d705-40dd-bb06-cb947c405eeb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Do not stop using Sogroya<sup>&reg;</sup> without discussing this with your doctor first.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_1229e93e-d5e5-4663-a0d4-f56917bd3ca6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>How much to use</strong></p><p>Children and adolescents</p><p>The dose for children and adolescents depends on the body weight.</p><p>The recommended dose of Sogroya<sup>&reg;</sup> is 0.16 mg per kg body weight given once a week.</p><p><u>&nbsp;</u></p><p>Adults</p><p>The usual starting dose is 1.5&nbsp;mg once a week if you are having growth hormone treatment for the first time. If you have been previously treated with daily growth hormone medicine (somatropin) the usual starting dose is 2&nbsp;mg once a week.</p><p>If you are a woman taking oral oestrogen (contraception or hormonal replacement therapy) you may need a higher dose of somapacitan. If you are above 60&nbsp;years, you may need a lower dose. See Table 1 below.</p><p>Your doctor may increase or decrease your dose step by step and regularly until you are on the right dose based on your individual needs and your experience of side effects.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use more than a maximum of 8&nbsp;mg once a week.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not change your dose unless your doctor has told you to.</p><p>&nbsp;</p><p>Table 1 Dose recommendation</p><table border="1" cellspacing="0" cellpadding="0" style="width:633px"><tbody><tr><td style="vertical-align:top"><p><strong>Adult growth hormone deficiency</strong></p></td><td style="vertical-align:top"><p><strong>Recommended starting dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>You have not received daily growth hormone medicine before</p><p>You are 18 to &lt; 60&nbsp;years</p><p>You are woman on oral oestrogen therapy regardless of age</p><p>You are 60&nbsp;years or above</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>1.5&nbsp;mg/week</p><p>2&nbsp;mg/week</p><p>&nbsp;</p><p>&nbsp;</p><p>1&nbsp;mg/week</p></td></tr><tr><td style="vertical-align:top"><p>You have previously received daily growth hormone medicine</p><p>You are &ge;18 to &lt;60&nbsp;years</p><p>You are woman on oral oestrogen therapy regardless of age</p><p>You are 60&nbsp;years or above</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>2&nbsp;mg/week</p><p>4&nbsp;mg/week</p><p>&nbsp;</p><p>&nbsp;</p><p>1.5&nbsp;mg/week</p></td></tr></tbody></table><p>&nbsp;</p><p>After you have reached your right dose, your doctor will evaluate your treatment every 6 to 12 months. You may need to have your body mass index checked and blood samples taken.</p><p>&nbsp;</p><p><strong>How Sogroya<sup>&reg;</sup></strong><strong> </strong><strong>is used</strong></p><p>Your doctor or nurse will show you how to inject Sogroya<sup>&reg;</sup> under your skin.</p><p>The best places to give the injection are:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the front of your thighs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the front of your waist (abdomen).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the buttocks</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the upper arms.</p><p>&nbsp;</p><p>Change the place of injection on your body from one week to the next.</p><p>Detailed instructions on how to inject Sogroya<sup>&reg;</sup>, the instructions for use, are included at the end of this booklet.</p><p><strong>&nbsp;</strong></p><p><strong>If you use more Sogroya<sup>&reg;</sup> </strong><strong>than you should</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;color:black;mso-themecolor:text1;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_667e47a1-6afc-4bb6-bb0e-29020230d661 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;color:black;mso-themecolor:text1;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you or the child in your care accidentally use more Sogroya<sup>&reg;</sup> than you should, talk to your doctor as your blood sugar levels may need to be checked.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_47d30845-3d8e-497c-86d2-87e5952e17d6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p><em>&nbsp;</em></p><p><strong>If you forget to use Sogroya<sup>&reg;</sup></strong><!--[if supportFields]><b><sup><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_eb5ba194-79d8-4bc0-9948-83afa8d37984 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b><sup><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p>If you or the child in your care forget to inject a dose:<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB;mso-no-proof:no'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_496cb4e9-0032-48f2-b96f-4f76e38d6add \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB;mso-no-proof:no'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and it is 3&nbsp;days or less after you should have used Sogroya<sup>&reg;</sup>, use it as soon as you remember. Then inject your next dose on your usual injection day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and it is more than 3&nbsp;days since you should have used Sogroya<sup>&reg;</sup>, skip the missed dose. Then inject your next dose as usual on your next scheduled day.</p><p>&nbsp;</p><p>Do not inject an extra dose or increase the dose to make up for a missed dose.</p><p><strong>&nbsp;</strong></p><p><strong>If you stop using Sogroya<sup>&reg;</sup></strong><!--[if supportFields]><b><sup><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0513b2a1-2e82-4124-901d-98f00ccd07c3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b><sup><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p>Do not stop using Sogroya<sup>&reg;</sup> without talking to your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Side effects seen in children and adolescents</strong></p><p>Very common (may affect more than 1&nbsp;in 10&nbsp;people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&nbsp;</p><p>Common (may affect up to 1&nbsp;in 10&nbsp;people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen hands and feet due to a build-up of fluid under the skin (peripheral oedema)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The adrenal glands do not make enough steroid hormones (adrenocortical insufficiency).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased thyroid hormone (hypothyroidism)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness and pain in the area of injection (injection site reactions)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain (arthralgia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in arms or legs (pain in extremity)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood sugar (hyperglycaemia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling very tired (fatigue).</p><p>&nbsp;</p><p><strong>Side effects seen in adults</strong></p><p>Very common (may affect more than 1&nbsp;in&nbsp;10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&nbsp;</p><p>Common (may affect up to 1&nbsp;in&nbsp;10 people)<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB;mso-no-proof:no'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_50f1bd9a-014d-42cc-97d7-12c69b1aa719 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-no-proof:
no'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The adrenal glands do not make enough steroid hormones (adrenocortical insufficiency)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased thyroid hormone (hypothyroidism)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood sugar (hyperglycaemia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling of &lsquo;pins and needles&rsquo; mainly in fingers (paraesthesia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (urticaria)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain (arthralgia), muscle pain (myalgia), muscle stiffness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen hands and feet due to a build-up of fluid under the skin (peripheral oedema)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling very tired or weak (fatigue or asthenia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness and pain in the area of injection (injection site reactions).</p><p>&nbsp;</p><p>Uncommon (may affect up to 1&nbsp;in&nbsp;100 people)<!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a7dbf4cb-e4fd-4dd8-8ef4-528b44e6acf4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thickening of skin where you inject your medicine (lipohypertrophy)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numb feeling and tingling in your hand(s) (carpal tunnel syndrome)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching (pruritus)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint stiffness.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Reporting of side effects</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_5fd1a301-b2f7-4adc-8ff2-54dec4eafa69 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><u>Please report adverse drug events to: </u></p><table border="1" cellspacing="1" cellpadding="1" style="width:100%"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the pen label and carton after &lsquo;Expiry&rsquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze. Keep away from the freezing element.</p><p><em>&nbsp;</em></p><p><em>After first opening</em></p><p>Use within 6&nbsp;weeks after first use. Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>&nbsp;</p><p><em>Before and after first opening</em></p><p>If you cannot refrigerate (for example during travelling), Sogroya<sup>&reg;</sup> may be kept temporarily at temperatures up to 30&deg;C for up to a total of 72&nbsp;hours (3&nbsp;days). Return Sogroya<sup>&reg;</sup> to the refrigerator again after storage at this temperature. If you store out of the refrigerator and then return to the refrigerator, the total combined time out of the refrigerator is 3&nbsp;days, monitor this carefully. Discard the Sogroya<sup>&reg;</sup> pen, if you have kept it at 30&deg;C for more than 72 hours, or for any period of time above 30&deg;C.</p><p>Record the time outside the refrigerator:________________</p><p>&nbsp;</p><p>Keep Sogroya<sup>&reg;</sup> in the outer carton with the pen cap on to protect from light.</p><p>Always remove the injection needle after each injection and store the pen without a needle attached.</p><p>&nbsp;</p><p>Do not use this medicine if the solution does not appear clear to slightly opalescent, colourless to slightly yellow and free from visible particles.<u> </u></p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Sogroya<sup>&reg;</sup></strong><strong> </strong><strong>contains </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is somapacitan. One mL of solution contains 3.3&nbsp;mg of somapacitan. Each pre‑filled pen contains 5&nbsp;mg of somapacitan in 1.5&nbsp;mL solution.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: histidine, mannitol, poloxamer&nbsp;188, phenol, water for injections, hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment). See also section&nbsp;&lsquo;2. What you need to know before you use Sogroya<sup>&reg;</sup>&rsquo; for information on sodium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Sogroya® looks like and contents of the pack
Sogroya® is a clear to slightly opalescent, colourless to slightly yellow liquid and free from visible particles for injection in a pre filled pen.
	
	Sogroya® 5 mg/1.5 mL solution for injection in pre filled pen with a teal dose button is available in the following pack size: a pack containing 1 pre-filled pen.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd</p><p>Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July-2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي سوجرويا&trade; على المادة الفعالة سوماباسيتان: عبارة عن نسخة ممتدة المفعول من هرمون النمو الطبيعي الذي ينتجه الجسم مع استبدال حمض أميني واحد. ينظم هرمون النمو تكوين الدهون والعضلات والعظام لدى البالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المادة الفعالة في سوجرويا&trade; مصنوعة من &quot;تقنية الحمض النووي المأشوب&quot;، أي من الخلايا التي تلقت جينًا (DNA) يجعلها تُنتج هرمون النمو. في سوجرويا&trade;، رُبطت سلسلة جانبية صغيرة بهرمون النمو الذي يربط سوجرويا&trade;<sup> </sup>بالبروتين (الألبومين) الموجود طبيعيًا في الدم لإبطاء عملية إزالته من الجسم، ممّا يسمح بإعطاء الدواء بمعدل أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم سوجرويا&trade; لعلاج فشل النمو لدى الأطفال والمراهقين الذين تبلغ أعمارهم 2.5 سنوات فأكثر إذا لم يكن لديهم إنتاج أو إنتاجهم منخفض جدا من هرمون النمو (نقص هرمون النمو) والبالغين الذين يُعانون من نقص هرمون النمو.</p><p dir="RTL">سيقيّم الطبيب المتابع لك بناءً على استجابتك لدواء سوجرويا&trade;، ما إذا كان ينبغي عليك مواصلة علاجك بدواء سوجرويا&trade;، بعد عام من بدء هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم سوجرويا&trade;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أو الطفل الذي تحت رعايتك تعاني من حساسية تجاه سوماباسيتان أو أي من المكونات الأخرى لهذا الدواء (مدرجة في القسم 6).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أو الطفل الذي تحت رعايتك تعاني من نمو ورم حميد أو خبيث. يجب أن تكون قد أكملت علاجك المضاد للورم قبل أن تبدأ علاجك بدواء سوجرويا&trade;. يجب إيقاف سوجرويا&trade; في حالة نمو الورم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا خضعت أو الطفل الذي تحت رعايتك مؤخرًا لجراحة قلب مفتوح أو جراحة بطنية أو إصابات عرضية متعددة أو مشكلات شديدة في التنفس أو حالة&nbsp;مشابهة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للأطفال والمراهقين الذين توقفوا عن النمو بسبب إغلاق صفائح النمو مما يعني أن طبيبك قد أخبرك أنت أو الطفل الذي في رعايتك أن عظامك قد توقفت عن النمو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا، فتحدث مع طبيبك أو الصيدلي أو الممرضة.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d834dced-4db4-4bb0-9487-c2bb5a1a4b53 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi;mso-ansi-font-weight:bold'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_0f887bdb-07eb-49e2-be65-4af698a44bdd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi;mso-ansi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استخدام سوجرويا&trade; إذا:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أصِبت أو الطفل الذي تحت رعايتك في أي وقت سابق بأي نوع من الأورام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني أو الطفل الذي تحت رعايتك من ارتفاع سكر الدم (فرط سكر الدم) حيث قد يلزم فحص مستوى سكر الدم لديك بانتظام وقد تكون هناك حاجة لتعديل جرعتك من دواء السكري</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تخضع أو الطفل الذي تحت رعايتك لعلاج بديل بالكورتيكوستيرويدات، لأنّك أُبلغت بأنّ جسمك لا ينتج ما يكفي منها (قصور قشرة الكُظر). تحدث مع طبيبك، لأن جرعتك قد تحتاج إلى تعديل على فترات منتظمة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني أو الطفل الذي تحت رعايتك من صداع شديد، أو مشاكل في الإبصار، أو غثيان، أو تقيؤ، فقد تكون هذه أعراضًا لزيادة ضغط الدماغ (فرط ضغط الدَّم الحميد داخل القِحْف) حيث قد تحتاج إلى إيقاف علاجك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني أو الطفل الذي تحت رعايتك من مشاكل في الغدة الدرقية، فيتعين فحص هرمونات الغدة الدرقية بانتظام وقد تحتاج إلى تعديل جرعتك من هرمون الغدة الدرقية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ امرأة تتناولين وسيلة منع حمل عن طريق الفم أو تتلقين علاج بالهرمونات البديلة باستخدام هرمون الإستروجين، فقد تحتاجين إلى زيادة جرعتك من سوجرويا&trade;. إذا توقفتِ عن تناول الإستروجين الفموي، فقد تحتاجين إلى تقليل جرعتك من سوماباسيتان. قد يوصيكِ طبيبكِ بتغيير طريقة إعطاء الإستروجين (على سبيل المثال، عبر الجلد، أو المهبل) أو استخدام وسيلة أخرى من وسائل منع الحمل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مريضًا أو الطفل الذي تحت رعايتك وحالتك خطرة (على سبيل المثال، المضاعفات التي تحدث بعد جراحة القلب المفتوح، أو جراحة بطنية، أو الصدمات العرضية، أو فشل الجهاز التنفسي الحاد، أو حالات مشابهة). إذا كنت على وشك الخضوع لعملية جراحية كبيرة أو خضعت لها سابقًا، أو ستذهب إلى المستشفى للأسباب المذكورة أعلاه، فأخبر طبيبك وذكّر الأطباء الآخرين ممن تتردد عليهم باستخدامك لهرمون النمو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت أنت أو الطفل في رعايتك تعاني من آلام شديدة في المعدة أثناء العلاج مع سوجرويا&trade; لأن هذا يمكن أن يكون أحد أعراض التهاب البنكرياس الذي لوحظ مع علاجات منتجات هرمون النمو الأخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p>تغيرات الجلد في موقع الحقن</p><p>يجب تدوير موقع حقن سوجرويا&trade; لمنع التغييرات في الأنسجة الدهنية تحت الجلد، مثل سماكة الجلد أو تقلص الجلد أو كتل تحت الجلد. غير مكان الحقن على جسمك من أسبوع إلى آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأجسام المضادة</p><p dir="RTL">من غير المتوقع أن تحصل على أجسام مضادة لسوماباسيتان. لكن، قد يحصل طفلك على أجسام مضادة في حالات نادرة. إذا لم يكن علاجك بسوجرويا&trade; فعالًا، فقد يجري لك طبيبك اختبارًا للتحقق من وجود أجسام مضادة لسوماباسيتان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى و سوجرويا&trade;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7de7cfdc-157d-40b2-8b78-d938a7d31d30 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يُرجى إخبار طبيبك أو الصيدلي ما إذا كنت تستخدم أو الطفل الذي تحت رعايتك أدوية أخرى أو استخدمتها مؤخرًا أو قد تستخدمها في المستقبل.</p><p dir="RTL">على وجه الخصوص، أخبر طبيبك إذا كنت أو الطفل الذي تحت رعايتك تتلقى أيًا من الأدوية التالية أو تلقيتها مؤخرًا.</p><p dir="RTL">وذلك لأن طبيبك قد يضطر إلى تعديل جرعات أدويتك:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات مثل الهيدروكورتيزون والديكساميثازون والبريدنيزولون</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإستروجين باعتباره أحد موانع الحمل التي تؤخذ عن طريق الفم أو علاج الهرمونات البديلة باستخدام هرمون الإستروجين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهرمونات الجنسية للذكور (أدوية الأندروجين) مثل التستوستيرون</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية الغونادوتروبين (هرمونات تحفيز الغدد التناسلية مثل الهرمون المُلَوتِن والهرمون المنبه للجريب) التي تحفز إنتاج الهرمونات الجنسية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأنسولين أو أدوية السكري الأخرى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية هرمون الغدة الدرقية مثل ليفوثيروكسين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج الصرع أو النوبات - مثل كاربامازيبين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيكلوسبورين (عقار كابت للمناعة) - دواء لتثبيط جهازك المناعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong><!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi;mso-ansi-font-weight:bold'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8c999c1a-85bd-4da5-a64e-c6b077175f74 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi;mso-ansi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ قادرة على الحمل، فيجب ألا تستخدمي سوجرويا&trade; إلا إذا كنتِ تستخدمين أيضًا وسيلة منع حمل موثوقة. وذلك لأنّه من غير المعروف ما إذا كان قد يُلحق الضرر بجنينك. إذا أصبحتِ حاملًا أثناء استخدامكِ لدواء سوجرويا&trade;، فتحدثي مع طبيبكِ على الفور. إذا كنتِ ترغبين في الحمل، فناقشي الأمر مع طبيبكِ، فقد تحتاجين إلى التوقف عن استخدام الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من غير المعروف ما إذا كان من الممكن أن ينتقل سوجرويا&trade; إلى حليب الثدي. أخبري طبيبكِ إذا كنتِ ترضعين رضاعة طبيعية أو تخططين لذلك. سيساعدكِ طبيبكِ حينها على اتخاذ قرار بشأن التوقف عن الرضاعة الطبيعية، أو التوقف عن تناول سوجرويا&trade;، مع الأخذ بعين الاعتبار فائدة الرضاعة الطبيعية للطفل، وفائدة سوجرويا&trade; للأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة المركبات واستخدام الآلات</strong></p><p dir="RTL">لا يؤثر سوجرويا&trade; على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسبة الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ميليمول صوديوم (23 مجم) لكل جرعة، &rlm;‫وهذا يعني أنه تقريبًا &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدواء دائمًا بدقة وفقًا لتعليمات طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">يُعطى سوجرويا&trade; كحقنة تحت الجلد من قلم مسبق التعبئة. يمكنك أخذ الحقنة بنفسك. سيخبرك طبيبك أو ممرضتك بالجرعة المناسبة وسيوضّحان لك كيفية إعطاء الحقنة عندما تبدأ أنت أو الطفل الذي تحت رعايتك العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى تستخدم سوجرويا&trade;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليك أو الطفل الذي تحت رعايتك استخدام سوجرويا&trade; مرة واحدة أسبوعيًا في نفس اليوم من كل أسبوع إن أمكن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك إعطاء نفسك الحقنة في أي وقت من اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت أنت أو الطفل الذي تحت رعايتك تقوم بالتغيير من علاج آخر أسبوعي بهرمون النمو إلى سوجرويا&trade;، فيُنصح بمواصلة الحقن في نفس يوم الأسبوع.</p><p dir="RTL">إذا كنت أنت أو الطفل الذي تحت رعايتك تقوم بالتغيير من علاج يومي بهرمون النمو إلى سوجرويا&trade;، فاختر اليوم المفضل للجرعة الأسبوعية وتناول الجرعة الأخيرة من العلاج اليومي في اليوم السابق (أو قبل 8 ساعات على الأقل) من تناول الجرعة الأولى من سوجرويا&trade;.</p><p dir="RTL">يجب إجراء التغيير من نوع أو علامة تجارية أخرى لهرمون النمو من قِبل طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم يكن من الممكن أن تأخذ أنت أو الطفل الذي تحت رعايتك سوجرويا&trade; في يومك المعتاد في الأسبوع، فيمكنك أخذ سوجرويا&trade; حتى يومين قبل يوم الجرعة المحدد أو بعده بمدة 3 أيام. ويمكنك تناول الجرعة التالية كالمعتاد في الأسبوع التالي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لزم الأمر، يمكنك تغيير يوم الحقن الأسبوعي بدواء سوجرويا&trade;<sup> </sup>طالما قد مر 4 أيام على الأقل منذ آخر حقنة لك من الدواء. بعد اختيار يوم جديد لتلقي الجرعة، استمر في إعطاء الحقنة لنفسك في ذلك اليوم كل أسبوع.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_10be858d-ec7b-47ee-9481-e8a80744c8f0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المدة التي ستحتاج إليها لعلاج</strong></p><p dir="RTL">قد تحتاج إلى أخذ سوجرويا&trade; طالما أن جسمك لا ينتج هرمون النمو الكافي</p><ul><li dir="RTL">إذا كنت أنت أو الطفل الذي تحت رعايتك تأخذ سوجرويا&trade; لعلاج فشل النمو، فستستمر في استخدامه سوجرويا&trade; حتى تتوقف عن النمو</li><li dir="RTL">إذا كنت أنت أو الطفل الذي تحت رعايتك لا تزال تفتقر إلى هرمون النمو بعد التوقف عن النمو، فقد تحتاج إلى الاستمرار في استخدام سوجرويا&trade; حتى مرحلة البلوغ</li><li dir="RTL">لا تتوقف عن استخدام سوجرويا&trade; دون مناقشة هذا الأمر مع طبيبك أولاً.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جرعة الاستخدام</strong></p><p dir="RTL">الأطفال والمراهقون</p><p dir="RTL">تعتمد جرعة الأطفال والمراهقين على وزن الجسم.</p><p dir="RTL">الجرعة الموصى بها من سوجرويا&trade; هي 0.16 مجم لكل كلجم من وزن الجسم تعطى مرة واحدة في الأسبوع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">البالغون</p><p dir="RTL">تبلغ جرعة البدء المعتادة 1.5 مجم مرة واحدة أسبوعيًا إذا كنت تتلقى علاج هرمون النمو لأول مرة. إذا سبق وعولجت بدواء هرمون النمو اليومي (سوماتروبين)، فإنّ جرعة البداية المعتادة 2 مجم مرة واحدة أسبوعيًا.</p><p dir="RTL">إذا كنتِ امرأة وتتناولين الإستروجين عن طريق الفم (موانع الحمل أو العلاج البديل بالهرمونات)، فقد تحتاجين إلى جرعة أعلى من سوماباسيتان. إذا كان عمرك يزيد عن 60 عامًا، فقد تحتاجين إلى جرعة أقل. انظر الجدول 1 أدناه.</p><p dir="RTL">قد يزيد طبيبك الجرعة أو يقللها تدريجيًا بصورة منتظمة حتى تحصل على الجرعة المناسبة بناءً على احتياجاتك الفردية وتعرّضك للآثار الجانبية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم أكثر من 8 مجم كحد أقصى مرة واحدة أسبوعيًا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تغير جرعتك إلا إذا طلب منك طبيبك ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجدول 1 الجرعة الموصى بها</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:633px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>نقص هرمون النمو لدى البالغين</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>جرعة البدء الموصى بها</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لم تتلقى دواء هرمون النمو اليومي من قبل</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتراوح عمرك 18 &ndash; أقل من 60 عامًا</p><p dir="RTL">أنتِ امرأة وتتناولين علاج الإستروجين عن طريق الفم بغض النظر عن العمر</p><p dir="RTL">عمرك 60 عامًا أو أكبر</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">1.5 مجم/أسبوعيًا</p><p dir="RTL">2 مجم/أسبوعيًا</p><p dir="RTL">&nbsp;</p><p dir="RTL">1 مجم/أسبوعيًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سبق لك تلقّي دواء هرمون النمو اليومي</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتراوح عمرك 18 &ndash; أقل من 60 عامًا</p><p dir="RTL">أنتِ امرأة وتتناولين علاج الإستروجين عن طريق الفم بغض النظر عن العمر</p><p dir="RTL">عمرك 60 عامًا أو أكبر</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">2 مجم/أسبوعيًا</p><p dir="RTL">4 مجم/أسبوعيًا</p><p dir="RTL">&nbsp;</p><p dir="RTL">1.5 مجم/أسبوعيًا</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">بعد أن تصل إلى الجرعة المناسبة لك، سيقيّم طبيبك علاجك كل 6 إلى 12 شهرًا. قد تحتاج للخضوع لفحص مؤشر كتلة جسمك وأخذ عينات دم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية استخدام سوجرويا&trade;</strong></p><p dir="RTL">سيوضح لك طبيبك أو الممرضة كيفية حقن سوجرويا&trade; تحت جلدك.</p><p dir="RTL">&rlm;‫وتعد أفضل الأماكن للحقن:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجزء الأمامي من فخذيك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجزء الأمامي من خصرك (البطن).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأرداف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجزء العلوي من الذراعين</p><p dir="RTL">&nbsp;</p><p dir="RTL">غيّر مكان الحقن في جسمك من أسبوع إلى آخر.</p><p dir="RTL">التعليمات المفصلة حول كيفية حقن سوجرويا&trade;، وتعليمات الاستخدام، مذكورة في نهاية هذا الكتيب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا استخدمت كمية أكبر مما ينبغي من سوجرويا&trade;</strong><!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi;mso-ansi-font-weight:bold'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_667e47a1-6afc-4bb6-bb0e-29020230d661 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi;mso-ansi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">إذا استخدمت أنت أو الطفل الذي تحت رعايتك<u> </u>سوجرويا&trade; أكثر مما ينبغي عن طريق الخطأ، فتحدث مع طبيبك حيث قد تحتاج إلى فحص مستويات السكر&nbsp;في&nbsp;دمك.<!--[if supportFields]><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_47d30845-3d8e-497c-86d2-87e5952e17d6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال نسيت استخدام سوجرويا&trade;</strong><!--[if supportFields]><b><sup><span lang=AR-SA
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_eb5ba194-79d8-4bc0-9948-83afa8d37984 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b><sup><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p dir="RTL">إذا نسيت أنت أو الطفل الذي تحت رعايتك<u> </u>حقن إحدى الجرعات:<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_496cb4e9-0032-48f2-b96f-4f76e38d6add \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وكان مر 3 أيام أو أقل على الموعد المحدد لاستخدام سوجرويا&trade;، فاستخدمه بمجرد أن تتذكر. ثم احقن جرعتك التالية في يوم الحقن المعتاد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وكان مر أكثر من 3 أيام على الموعد المحدد لاستخدام سوجرويا&trade;، فتخطى الجرعة الفائتة. ثم احقن جرعتك التالية كالمعتاد في يومك التالي المقرر لذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تحقن جرعة إضافية أو تزيد الجرعة لتعويض جرعة فائتة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن استخدام</strong> <strong>سوجرويا&trade;</strong></p><p dir="RTL">لا تتوقف عن استخدام سوجرويا&trade; دون التحدث مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فاسأل الطبيب أو الصيدلي أو الممرضة المتابعين لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من ذلك لا يُصاب جميع المستخدمين بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية التي لوحظت لدى الأطفال والمراهقين </strong></p><p dir="RTL">شائعة جداً (قد تصيب أكثر من شخص واحد من كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp; صُداع</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp; تورم اليدين والقدمين بسبب تراكم السوائل تحت الجلد (وَذَمَة محيطية)</p><p dir="RTL">&bull;&nbsp;&nbsp; لا تنتج الغدد الكظرية ما يكفي من هرمونات الستيرويد (قصور القشرة الكظرية)</p><p dir="RTL">&bull;&nbsp;&nbsp; انخفاض هرمون الغدة الدرقية (قصور الدرقية)</p><p dir="RTL">&bull;&nbsp;&nbsp; احمرار وألم في منطقة الحقن (ردود فعل موضع الحقن).</p><p dir="RTL">&bull;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp; ارتفاع السكر في الدم (فرط سكر الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp; الشعور بإجهاد الشديد.</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL"><strong>الآثار الجانبية التي لوحظت لدى البالغين</strong></p><p dir="RTL"><strong>شائعة جدًا (قد تصيب أكثر من شخص واحد</strong><strong>&nbsp;من كل&nbsp;10 أشخاص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تصيب شخصًا واحدًا من كل 10 أشخاص)</strong><!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_50f1bd9a-014d-42cc-97d7-12c69b1aa719 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تنتج الغدد الكظرية ما يكفي من هرمونات الستيرويد (قصور القشرة الكظرية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض هرمون الغدة الدرقية (قصور الدرقية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع سكر الدم (فرط سكر الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور &quot;بوخز&quot; بصورة أساسية في الأصابع (التنميل)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (حساسية الجلد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل (ألم مفصلي)، ألم العضلات (ألم عضلي)، تصلب العضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين والقدمين بسبب تراكم السوائل تحت الجلد (وَذَمَة محيطية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب أو الضعف الشديد (الإعياء أو الوهن)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار وألم في منطقة الحقن (ردود فعل موضع الحقن).</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة (قد تصيب شخصًا واحدًا من كل 100 شخص)<!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a7dbf4cb-e4fd-4dd8-8ef4-528b44e6acf4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]-->&nbsp;<!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سماكة الجلد في موضع حقن الدواء (التضخم الشحمي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالخدر والوخز في يدك(يديك) (متلازمة النفق الرسغي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة (الهراش)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب المفاصل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong><!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi;mso-ansi-font-weight:bold'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_5fd1a301-b2f7-4adc-8ff2-54dec4eafa69 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:
minor-bidi;mso-ansi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى الإبلاغ عن الأعراض الجانبية إلى:</p><table border="1" cellspacing="1" cellpadding="1" style="width:100%"><tbody><tr><td><p>المركز الوطني للتيقظ والسلامة الدوائية:</p><p>+966-11- فاكس: 2057662</p><p>للاتصال بالمركز الموحد للهيئة العامة للغذاء والدواء: 19999</p><p>npc.drug@sfda.gov.sa بريد الالكتروني:</p><p>https://ade.sfda.gov.sa الموقع الالكتروني:</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تجنب استخدام هذا الدواء بعد تاريخ انتهاء الصلاحية المكتوب على ملصق قلم الحقن والعلبة الكرتونية بعد كلمة &quot;Expiry&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظه في الثلاجة (من 2 درجة مئوية - 8 درجات مئوية). لا تجمده. اجعل الدواء بعيدًا عن مكان التجميد.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>بعد فتحه لأول مرة</em></p><p dir="RTL">استخدمه في غضون 6 أسابيع بعد أول استخدام. احفظه في الثلاجة (من 2 درجة مئوية - 8 درجات مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>قبل وبعد فتحه لأول مرة</em></p><p dir="RTL">إذا لم تتمكن من تبريده (على سبيل المثال أثناء السفر)، فيجوز حفظ دواء سوجرويا&trade; مؤقتًا في درجات حرارة تصل إلى 30&nbsp;درجة مئوية لمدة تصل إلى 72 ساعة (3 أيام) كحد أقصى. أعد سوجرويا&trade; إلى الثلاجة مرة أخرى بعد تخزينه في درجة الحرارة هذه. إذا خزنته خارج الثلاجة ثم أعدته إلى الثلاجة، فإن إجمالي حساب الوقت خارج الثلاجة هو 3 أيام، فراقب ذلك بعناية. تخلص من قلم سوجرويا&trade;، إذا احتفظت به عند درجة حرارة 30 درجة مئوية لأكثر من 72 ساعة، أو لأي فترة زمنية أعلى من 30 درجة مئوية.</p><p dir="RTL">سَجِّل الوقت خارج الثلاجة:__________________</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بقلم سوجرويا&trade;<sup> </sup>مع غطاءه في العبوة الكرتونية الخارجية لحمايته من الضوء.</p><p dir="RTL">دائماً أزل الإبرة بعد كل حقن، وخزن قلمك بدون إبرة مركبة به.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تجنب استخدام هذا الدواء إذا لم يكن المحلول لايبدو صافيًا إلى غميم بشكل طفيف، وعديم اللون إلى أصفر قليلًا وخالي من أي جزيئات مرئية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تجنب التخلص من أيّة أدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي المتابع لك عن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تركيبة دواء سوجرويا&trade;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي سوماباسيتان. يحتوي الميلليلتر الواحد من المحلول على 3.3 مجم من سوماباسيتان. يحتوي كل قلم معبأ مسبقًا على 5 مجم من سوماباسيتان في 1.5 مل من المحلول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى: الهيستيدين، المانيتول، بولوكسامير 188، الفينول، ماء للحقن، حمض الهيدروكلوريك (لتعديل درجة الحموضة)، وهيدروكسيد الصوديوم (لتعديل درجة الحموضة). انظر أيضًا القسم &rsquo;2. ما تحتاج إلى معرفته قبل استخدامك سوجرويا&trade;&rsquo; للحصول على معلومات بشأن الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل</strong> <strong>سوجرويا&trade;<sup> </sup>ومحتويات العبوة</strong></p><p dir="RTL">سوجرويا&trade; عبارة عن سائل شفاف إلى غميم قليلًا، عديم اللون إلى أصفر قليلًا وخالٍ من الجسيمات المرئية للحقن في قلم معبأ&nbsp;مسبقًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر سوجرويا&trade; في صورة محلول 5 مجم/1.5 مل للحقن في قلم معبأ مسبقًا مع زر ذو لون شرشيري مخضر في حجم العبوة التالي: عبوة تحتوي على قلم واحد معبأ مسبقًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd</p><p dir="RTL">Denmark</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو-2023    
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sogroya® 5 mg/1.5 mL solution for injection in pre filled pen 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One mL of solution cotains 3.3 mg of somapacitan*
Each pre filled pen contains 5 mg of somapacitan in 1.5 mL solution

*Produced by recombinant DNA technology in Escherichia coli followed by attachment of an albumin binding moiety.

For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).
Clear to slightly opalescent, colourless to slightly yellow liquid, essentially free from visible particles. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sogroya<sup>&reg;</sup> is indicated for the replacement of endogenous growth hormone (GH) in children aged 2.5 years and above and adolescents with growth failure due to growth hormone deficiency (paediatric GHD) and in adults with growth hormone deficiency (adult GHD).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Somapacitan should be initiated and monitored by physicians who are appropriately qualified and experienced in the diagnosis and management of patients with growth hormone deficiency (e.g. endocrinologists).</p><p>&nbsp;</p><p><u>Posology</u></p><p><em><s>&nbsp;</s></em></p><p><strong>Table 1: Dose recommendation</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:633px"><tbody><tr><td style="vertical-align:top"><p><strong>Paediatric GHD </strong></p></td><td style="vertical-align:top"><p><strong>Recommended starting dose </strong></p></td></tr><tr><td style="vertical-align:top"><p>Treatment-na&iuml;ve paediatric patients and paediatric patients switching from other GH medicinal products</p></td><td style="vertical-align:top"><p>0.16 mg/kg/week</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adult GHD</strong></p></td><td style="vertical-align:top"><p><strong>Recommended starting dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Na&iuml;ve patients</p><p>Adults (&ge;18 to &lt;60&nbsp;years)</p><p>Women on oral oestrogen therapy (irrespective of age)</p><p>Elderly (60&nbsp;years or older)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.5&nbsp;mg/week</p><p>2&nbsp;mg/week</p><p>&nbsp;</p><p>1&nbsp;mg/<em>week</em></p></td></tr><tr><td style="vertical-align:top"><p>Patients switching from daily GH medicinal products</p><p>Adults (&ge;18 to &lt;60&nbsp;years)</p><p>Women on oral oestrogen therapy (irrespective of age)</p><p>Elderly (60&nbsp;years or older)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>2&nbsp;mg/week</p><p>4&nbsp;mg/week</p><p>&nbsp;</p><p>1.5&nbsp;mg/week</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Paediatric GHD</em></p><p><em>Dose titration</em></p><p>Somapacitan dose may be individualised and adjusted based on growth velocity, adverse reactions, body weight and serum insulin-like growth factor I (IGF-I) concentrations.</p><p>&nbsp;</p><p>Average IGF-I standard deviation score (SDS) levels (drawn 4 days after dosing) can guide dose titration. Dose adjustments should be targeted to achieve average IGF-I SDS levels in the normal range, i.e. between -2 and +2 (preferably close to 0 SDS).</p><p>&nbsp;</p><p>If the IGF-I (SDS) is &gt;&nbsp;2, it should be reassessed after a subsequent somapacitan administration. If the value remains &gt;&nbsp;2, reducing the dose by 0.04&nbsp;mg/kg/week is recommended. More than one dose reduction may be required in some patients.</p><p>&nbsp;</p><p>In patients who have had the dose reduced but are not growing well, the dose may be gradually increased as tolerated up to a maximum dose of 0.16 mg/kg/week. Dose increments should not exceed 0.02 mg/kg per week.</p><p><em>&nbsp;</em></p><p><em>Treatment evaluation</em></p><p>Evaluation of efficacy and safety should be considered at approximately 6- to 12-month intervals and may be assessed by evaluating auxological parameters, biochemistry (IGF-I, hormones, glucose, and lipid levels) and pubertal status. More frequent evaluations should be considered during puberty.</p><p>&nbsp;</p><p>Treatment should be discontinued in patients having achieved final height or near final height, i.e. an annualised height velocity &lt;&nbsp;2&nbsp;cm/year and a bone age &gt;&nbsp;14&nbsp;years in girls or &gt;&nbsp;16&nbsp;years in boys which corresponds to the closure of the epiphyseal growth plates, see section 4.3. Once the epiphyses are fused, patients should be clinically re-evaluated for the need for growth hormone treatment.</p><p>&nbsp;</p><p>When GHD persists after growth completion, growth hormone treatment should be continued to achieve full somatic adult development including lean body mass and bone mineral accrual (for guidance on dosing see recommended dose for adults (Table 1)).</p><p><em>&nbsp;</em></p><p><em>Adult GHD</em></p><p><em>Dose titration</em></p><p>The somapacitan dose must be individually adjusted for each patient. It is recommended to increase the dose gradually with 2-4&nbsp;weeks intervals in steps from 0.5&nbsp;mg to 1.5&nbsp;mg based on the patients&rsquo; clinical response and experience of adverse reactions up to a dose of 8&nbsp;mg somapacitan per week.</p><p>Serum insulin like growth factor-I (IGF-I) levels (drawn 3-4&nbsp;days after dosing) can be used as guidance for the dose titration. The IGF-I standard deviation score (SDS) target should aim for the upper normal range not exceeding 2 SDS. IGF-I SDS levels in the target range are usually achieved within 8&nbsp;weeks of dose titration. Longer dose titration may be necessary in some <s>A</s> adult GHD patients (see below and section 5.1).</p><p>&nbsp;</p><p><em>Treatment evaluation</em></p><p>Using IGF-I SDS as a biomarker for dose titration, the aim is to reach IGF-I SDS levels within the age-adjusted upper reference range (IGF-I SDS upper reference range: 0 and +2) within 12 months of titration. If this target range cannot be achieved within this period, or the patient does not obtain the desired clinical response, other treatment options should be considered.</p><p>&nbsp;</p><p>During somapacitan maintenance treatment, evaluation of efficacy and safety should be considered at approximately 6- to 12-month intervals and may be assessed by evaluating biochemistry (IGF-I-, glucose-, and lipid levels), body composition, and body mass index.</p><p>&nbsp;</p><p><em>Paediatric and adult GHD</em></p><p><em>Switching from other growth hormone products </em></p><p>Patients switching from a weekly growth hormone to somapacitan are recommended to continue administration at their once weekly dosing day.</p><p>Patients switching from daily human growth hormone to once-weekly somapacitan should choose the preferred day for the weekly dose and inject the final dose of daily treatment the day before (or at least 8&nbsp;hours before) injecting the first dose of once-weekly somapacitan. Patients should follow the instructions for the dose presented in Table 1.</p><p>&nbsp;</p><p><em>Oral oestrogen therapy</em></p><p>Females on oral oestrogen-containing therapy may have reduced IGF-I levels and may require dose adjustment of growth hormone to achieve the treatment goal (see section 4.4).</p><p>In paediatric GHD doses above 0.16&nbsp;mg/kg/week have not been studied and are not recommended.</p><p>&nbsp;</p><p><em>Missed dose</em></p><p>Patients who miss a dose are advised to inject once-weekly somapacitan upon discovery as soon as possible, within 3&nbsp;days after the missed dose, and then resume their usual once-weekly dosing schedule. If more than 3&nbsp;days have passed, the dose should be skipped and the next dose should be administered on the regularly scheduled day. If two or more doses have been missed, the dose should be resumed on the regularly scheduled day.</p><p>&nbsp;</p><p><em>Changing the dosing day</em></p><p>The day of weekly injection can be changed as long as the time between two doses is at least 4&nbsp;days. After selecting a new dosing day, the once weekly dosing should be continued.</p><p>&nbsp;</p><p><em>Flexibility in dosing time</em></p><p>On occasions when injection at the scheduled dosing day is not possible, once-weekly somapacitan can be administered up to 2&nbsp;days before or 3&nbsp;days after the scheduled weekly dosing day as long as the time between two doses is at least 4&nbsp;days (96&nbsp;hours). Once-weekly dosing for the next dose could be resumed at the regularly scheduled dosing day.</p><p>&nbsp;</p><p><u>Special population</u><u>s</u></p><p><em>&nbsp;</em></p><p><em>Elderly (60&nbsp;years or older</em><em>)</em></p><p>Generally, lower doses of somapacitan may be necessary in older patients. For further information, see section 5.2.</p><p>&nbsp;</p><p><em>Gender</em></p><p>Men show an increasing IGF-I sensitivity over time. This means that there is a risk that men are overtreated. Women, especially those on oral oestrogen, may require higher doses and a longer titration period than men, see sections 5.1 and<em> </em>5.2<em>. </em>In female using oral oestrogen, it should be considered to change the route of oestrogen administration (e.g. transdermal, vaginal) see section 4.4.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No adjustment of the starting dose is required for patients with renal impairment. Patients with renal impairment may need lower doses of somapacitan but since the dose of somapacitan is individually adjusted according to the need of each patient, no further dose adjustment is required, see section 5.2.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No adjustment of the starting dose is required for patients with hepatic impairment. Patients with moderate hepatic impairment may need higher doses of somapacitan but since the dose of somapacitan is individually adjusted according to the need of each patient, no further dose adjustment is required. No information regarding the use of somapacitan in patients with severe hepatic impairment is available. Caution should be exercised if treating these patients with somapacitan, see section 5.2.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>&nbsp;</p><p>Somapacitan is to be administered once-weekly at any time of the day.</p><p>&nbsp;</p><p>Somapacitan is to be injected subcutaneously in the abdomen, thighs, buttocks or upper arms without dose adjustment.</p><p>&nbsp;</p><p>The Sogroya<sup>&reg;</sup> 5&nbsp;mg/1.5&nbsp;mL (3.3&nbsp;mg/mL) pen delivers doses from 0.025&nbsp;mg (0.0075 mL) to 2&nbsp;mg (0.6 mL) in increments of 0.025&nbsp;mg</p><p>&nbsp;</p><p>For instructions of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Somapacitan must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting somapacitan therapy. Treatment should be discontinued if there is evidence of tumour growth, see section 4.4.

Somapacitan must not be used for longitudinal growth promotion in children with closed epiphyses, see section 4.2.

Patients with acute critical illness suffering from complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions must not be treated with somapacitan (regarding patients undergoing substitution therapy, see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><u>&nbsp;</u></p><p><u>Adrenocortical insufficiency</u></p><p>&nbsp;</p><p>Introduction of growth hormone treatment may result in inhibition of 11&beta;HSD-1 and reduced serum cortisol concentrations. In patients treated with growth hormone, previously undiagnosed central (secondary) hypoadrenalism may be unmasked and glucocorticoid replacement may be required. In addition, patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of growth hormone treatment. It is necessary to monitor patients with known hypoadrenalism for reduced serum cortisol levels and/or for the need of increased doses of glucocorticoid, see section 4.5.</p><p><u>&nbsp;</u></p><p><u>Glucose metabolism impairment</u></p><p>&nbsp;</p><p>Treatment with growth hormone may decrease insulin sensitivity, particularly at higher doses in susceptible patients and consequently hyperglycaemia may occur in subjects with inadequate insulin secretory capacity. As a result, previously undiagnosed impaired glucose tolerance and overt diabetes mellitus may be unmasked during growth hormone treatment. Therefore, glucose levels should be monitored periodically in all patients treated with growth hormone, especially in those with risk factors for diabetes mellitus, such as obesity, or a family history of diabetes mellitus. Patients with pre-existing type 1 or type 2 diabetes mellitus or impaired glucose tolerance should be monitored closely during growth hormone therapy. The doses of antihyperglycaemic medicinal products may require adjustment when growth hormone therapy is instituted in these patients.</p><p>&nbsp;</p><p><u>Neoplasms</u></p><p>&nbsp;</p><p>There is no evidence for increased risk of new primary cancers in patients treated with growth hormone.</p><p>&nbsp;</p><p>In patients in complete remission from malignant diseases or who have been treated for benign tumours, growth hormone therapy has not been associated with an increased relapse rate.</p><p>Patients who have achieved complete remission of malignant diseases or who have been treated for benign tumours should be followed closely for relapse after commencement of growth hormone therapy. Growth hormone treatment should be interrupted in case of any development or reoccurrence of malignant or benign tumour.</p><p>An overall slight increase in second neoplasms has been observed in childhood cancer survivors treated with growth hormone, with the most frequent being intracranial tumours. The dominant risk factor for secondary neoplasms seems to be prior exposure to radiation.</p><p>&nbsp;</p><p><u>Benign intracranial hypertension</u></p><p>&nbsp;</p><p>In the event of severe or recurrent headache, visual symptoms, nausea, and/or vomiting, a fundoscopy for papilloedema is recommended. If papilloedema is confirmed, a diagnosis of benign intracranial hypertension should be considered and if appropriate the growth hormone treatment should be discontinued. At present there is insufficient evidence to guide clinical decision making in patients with resolved intracranial hypertension. If growth hormone treatment is restarted, careful monitoring for symptoms of intracranial hypertension is necessary.</p><p>&nbsp;</p><p><u>Thyroid function</u></p><p>&nbsp;</p><p>Growth hormone increases the extrathyroidal conversion of T4 to T3 and may as such unmask incipient hypothyroidism. As hypothyroidism interferes with the response to growth hormone therapy, patients should have their thyroid function tested regularly and should receive replacement therapy with thyroid hormone when indicated, see sections 4.5 and 4.8.</p><p>&nbsp;</p><p><u>Use with oral oestrogen</u></p><p><u>&nbsp;</u></p><p>Oral oestrogen influences the IGF-I response to growth hormone including somapacitan. Female<u> </u>patients taking any form of oral oestrogen (hormone therapy or contraception) should consider changing the route of oestrogen administration (e.g. transdermal-, vaginal hormone products) or use another form of contraception. If a woman on oral oestrogen is starting somapacitan therapy, higher starting doses and a longer titration period may be required (see section 4.2).</p><p>If a female patient taking somapacitan begins oral oestrogen therapy, the dose of somapacitan may need to be increased to maintain the serum IGF-I levels within the normal age-appropriate range. Conversely, if a female patient on somapacitan discontinues oral oestrogen therapy, the dose of somapacitan may need to be reduced to avoid excess of somapacitan and/or undesirable effects, see sections 4.2 and 4.5.</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders</u></p><p><u>&nbsp;</u></p><p>When somapacitan is administered at the same site over a long<u>er</u> period of time, local changes in the subcutaneous tissue such as lipohypertrophy lipoatrophy, and acquired lipodystrophy might occur. The injection site should be rotated to minimise <s>reduce</s> the risk, see sections 4.2 and 4.8.</p><p>&nbsp;</p><p><u>Antibodies</u></p><p><u>&nbsp;</u></p><p>Antibodies to somapacitan were not observed in adult GHD patients. Few paediatric GHD patients tested positive for somapacitan binding antibodies. None of these antibodies were neutralising and no impact on the clinical effects was observed. Testing for presence of anti-somapacitan antibodies should be carried out in patients who fail to respond to therapy.</p><p>&nbsp;</p><p><u>Acute critical illness</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_76d52100-815f-4e68-bf9c-843498b40474 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p><u>&nbsp;</u></p><p>The effect of growth hormone on recovery was studied in two placebo controlled trials involving 522&nbsp;critical ill adult patients suffering from complications following open heart surgery, abdominal surgery, multiple accidental trauma or acute respiratory failure. Mortality was higher in patients treated with 5.3 or 8&nbsp;mg growth hormone daily compared to patients receiving placebo, 42% vs 19%. Based on this information, these types of patients should not be treated with somapacitan. As there is no information available on the safety of growth hormone substitution therapy in acutely critical ill patients, the benefits of continued treatment in this situation should be weighed against the potential risks involved.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_4f4a7757-d83b-4416-8e2f-7d1feda7142a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Growth hormone deficiency in adults is a lifelong disease and needs to be treated accordingly, however, experience in patients older than 60&nbsp;years and in patients with more than five years of treatment in adult growth hormone deficiency is still limited.<!--[if supportFields]><span
style='mso-bookmark:_Hlk55980854'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk55980854'><span style='mso-bidi-font-size:11.0pt'>
DOCVARIABLE vault_nd_eae7c654-ef27-4802-9b56-4b98d03fca0d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Hlk55980854'></span><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p><u>Pancreatitis</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB;mso-bidi-font-weight:bold;mso-bidi-font-style:italic'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f2e43c4d-800b-4755-9a2f-19bf69536e89 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB;mso-bidi-font-weight:bold;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p><u>&nbsp;</u></p><p>There have been few reports of pancreatitis during treatment with other growth hormone medicinal products. It should therefore be considered in somapacitan treated patients who develop unexplained abdominal pain.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB;mso-bidi-font-weight:bold;mso-bidi-font-style:italic'><span
style='mso-element:field-begin'></span> DOCVARIABLE vault_nd_85930660-0d55-41de-a691-71f9a8ed0829
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
mso-ansi-language:EN-GB;mso-bidi-font-weight:bold;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>Sodium</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_742b8134-9a2b-45b4-8ca8-7dd9ba092458 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23&nbsp;mg) per dose, i.e. it is essentially sodium-free.<!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_2fd47cfd-f73b-41d4-8164-43a6efe961ce \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cytochrome P450 metabolised drugs</u></p><p>&nbsp;</p><p>Data from an interaction study performed in growth hormone deficient adults suggests that growth hormone administration may increase the clearance of compounds known to be metabolised by cytochrome P450 isoenzymes. The clearance of compounds metabolised by cytochrome P450 (e.g. sex steroids, corticosteroids, anticonvulsants and cyclosporine) may be especially increased resulting in lower plasma levels of these compounds. The clinical significance of this is unknown.</p><p>&nbsp;</p><p><u>Glucocorticoids</u></p><p>&nbsp;</p><p>Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective, see section 4.4.</p><p>&nbsp;</p><p><u>Oral oestrogens</u></p><p>&nbsp;</p><p>In female on oral oestrogen therapy, a higher dose of somapacitan may be required to achieve the treatment goal, see sections 4.2 and 4.4.</p><p>&nbsp;</p><p><u>Antihyperglycaemic products</u></p><p>&nbsp;</p><p>Antihyperglycaemic treatment including insulin may require dose adjustment in case of somapacitan co-administration since somapacitan may decrease insulin sensitivity, see sections 4.4 and 4.8.</p><p><u>&nbsp;</u></p><p><u>Other</u></p><p>&nbsp;</p><p>The metabolic effects of somapacitan can also be influenced by concomitant therapy with other hormones, e.g. testosterone and thyroid hormones, see section 4.4.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no data from the use of somapacitan in pregnant women.</p><p>Studies in animal have shown reproductive toxicity, see section 5.3.</p><p>Sogroya<sup>&reg;</sup> is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether somapacitan/metabolites are excreted in human milk.</p><p>Available pharmacodynamic/toxicological data in animals have shown excretion of somapacitan in milk, see section 5.3.</p><p>A risk to the breastfed newborns/infants cannot be excluded.</p><p>A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Sogroya<sup>&reg;</sup> therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>&nbsp;</p><p>There is no clinical experience with somapacitan use and its potential effect on fertility.</p><p>No adverse effects were observed on male and female fertility in rats,see section 5.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sogroya<sup>&reg;</sup> has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>&nbsp;</p><p>The commonly most frequently reported &nbsp;adverse drug reactions (ADRs) are (in decreasing order [paediatric GHD, adult GHD]) headache (12%, 12%), pain in extremity (9%, NA), hypothyroidism (5%, 2%), injection site reactions (5%, 1%), peripheral oedema (3%, 4%), arthralgia (2%, 7%), hyperglycaemia (2%, 1%), fatigue (2%, 6%) and adrenocortical insufficiency (1.5%, 3%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The ADRs listed in Table 2 are based on the safety data from one ongoing pivotal phase 3 trial (52&nbsp;weeks) in paediatric patients with GHD (baseline age: 2.5 to 11&nbsp;years) and adverse reactions from somapacitan treatment. The frequencies of the ADRs have been calculated based on the frequencies in the pivotal phase 3 trial.</p><p>&nbsp;</p><p>The adverse reactions listed in Table 3 are based on the compiled safety data from three completed phase 3 trials in adults patients with <s>A</s>GHD (baseline age 19 to 77 years).</p><p>&nbsp;</p><p>The ADRs are listed by MedDRA system organ class and frequency category defined as: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><p>&nbsp;</p><p><strong>Table 2: Adverse reactions from phase 3 clinical trials in paediatric GHD</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA </strong></p><p><strong>system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Adrenocortical insufficiency<br />Hypothyroidism*</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache*</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia<br />Pain in exteremity**</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peripheral oedema*<br />Fatigue<br />Injection site reactions*#</p></td></tr></tbody></table><p>*In general, these adverse reactions were non-serious, of mild severity and transient</p><p><strong><sup>#</sup></strong>The injection site reactions included injection site bruising (1.5%), injection site pain (1.5%), injection site haematoma (1.5%), and injection site swelling (0.8%).</p><p>**Primarily mild leg pain</p><p>&nbsp;</p><p><strong>Table 3: Adverse reactions from three completed phase 3 trials in adult patients with GHD</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA </strong></p><p><strong>system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Adrenocortical insufficiency<br />Hypothyroidism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperglycaemia*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Carpal tunnel syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash*<br />Urticaria*</p></td><td style="vertical-align:top"><p>Lipohypertrophy*<br />Pruritus*</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia<br />Myalgia<br />Muscle stiffness*</p></td><td style="vertical-align:top"><p>Joint stiffness</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peripheral oedema<br />Fatigue<br />Asthenia<br />Injection site reactions*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*In general, these adverse reactions were non-serious, mild or moderate severity and transient</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Peripheral oedema </em></p><p>Peripheral oedema was commonly observed (3% in paediatric GHD and 4% in adult GHD). Growth hormone deficient patients are characterised by extracellular volume deficit. When treatment with growth hormone products is initiated, this deficit is corrected. Fluid retention with peripheral oedema may occur. The symptoms are usually transient, dose dependent and may require transient dose reduction.</p><p>&nbsp;</p><p><em>Adrenocortical insufficiency</em></p><p>Adrenocortical insufficiency was commonly observed (1.5% in paediatric GHD and 3% in adult GHD), see section 4.4.</p><p>&nbsp;</p><p><u>Please report adverse drug events to: </u></p><table border="1" cellspacing="1" cellpadding="1" style="width:303px"><tbody><tr><td style="width:300px"><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited clinical experience with overdose of somapacitan.</p><p>Based on expeireince with growth hormone treatement, short term overdose with low blood glucose levels initially, followed by high blood glucose levels can occur. These decreased glucose levels have been detected biochemically, but without clinical signs of hypoglycaemia.</p><p>Long-term overdosage could result in signs and symptoms consistent with the known effects of human growth hormone excess.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Pituitary and hypothalamic hormones and analogues, somatropin and somatropin agonists, ATC code: H01AC07.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_368ff32f-3b3c-4bf6-845c-031e2810fbb2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Somapacitan is a long-acting recombinant human growth hormone derivative. It consists of 191 amino acids similar to endogenous human growth hormone, with a single substitution in the amino acid backbone (L101C) to which an albumin binding moiety has been attached. The albumin binding moiety (side‑chain) consists of a fatty acid moiety and a hydrophilic spacer attached to position 101 of the protein.</p><p>The mechanism of action of somapacitan is either directly via the GH‑receptor and/or indirectly via IGF‑I produced in tissues throughout the body, but predominantly by the liver.</p><p>When growth hormone deficiency is treated with somapacitan a normalisation of body composition (i.e., decreased body fat mass, increased lean body mass) and of metabolic action is achieved.</p><p>&nbsp;</p><p>Somapacitan stimulates skeletal growth in paediatric patients with GHD as a result of effects on the growth plates (epiphyses) of bones, see section 5.3.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><em>IGF</em>‑<em>I </em></p><p>IGF‑I is a generally accepted biomarker for efficacy in GHD.</p><p>A dose-dependent IGF‑I response is induced following somapacitan administration.</p><p>A steady state pattern in IGF-I responses is reached after 1-2 weekly doses.</p><p>The IGF-I levels fluctuate during the week. The IGF‑I response is maximal after 2&nbsp;to 4&nbsp;days. Compared with daily GH treatment, the IGF‑I profile of somapacitan differs, see Figure 1.</p><p>&nbsp;</p><p>In paediatric GHD patients somapacitan produces a dose linear IGF-I response, with a change of 0.02&nbsp;mg/kg on average resulting in a change in IGF-I standard deviation score (SDS) of 0.32.</p><p><img alt="" width="598" height="333" src="data:image/png;base64,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" /></p><p><strong>Figure 1: Model-derived IGF</strong>‑<strong>I profiles during steady state of somapacitan and somatropin (based on data from adult GHD)</strong></p><p><strong>&nbsp;</strong></p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p><em>Paediatric GHD</em></p><p><em>REAL 4 (phase 3)</em></p><p>The efficacy and safety of once weekly somapacitan was evaluated in a 52 weeks randomised, multi-center, open-label, active-controlled, parallel-group phase 3 trial (REAL 4) in 200 treatment-na&iuml;ve, paediatric patients with GHD. Patients were randomised to 0.16&nbsp;mg/kg/week once weekly somapacitan (N=132) or 0.034&nbsp;mg/kg/day once daily somatropin (N=68).</p><p>&nbsp;</p><p>At baseline, the 200 patients had a mean age of 6.4&nbsp;years (range: 2.5 to 11&nbsp;years). 74.5% of the patients were male.</p><p>&nbsp;</p><p>The annualised height velocity at week 52 was similar for somapacitan and somatropin (Table 4).</p><p>&nbsp;</p><p><strong>Table 4: Growth results at week 52 in paediatric patients with GHD</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Once-weekly somapacitan</p><p>(N=132)</p></td><td style="vertical-align:top"><p>Once-daily somatropin</p><p>(N=68)</p></td><td style="vertical-align:top"><p>Estimate of treatment difference (95% CI) (somapacitan minus somatropin)</p></td></tr><tr><td><p>Annualised height velocity (cm/year)</p></td><td style="vertical-align:top"><p>11.2</p></td><td style="vertical-align:top"><p>11.7</p></td><td style="vertical-align:top"><p>-0.5 [-1.1;&nbsp;0.2]</p></td></tr></tbody></table><p>In accordance with this, changes at week 52 compared to baseline with respect to the height SDS and IGF-I SDS were also similar for somapacitan and somatropin (Table 5).</p><p>&nbsp;</p><p><strong>Table </strong><strong>5: Height SDS and IGF-I SDS in paediatric patients with GHD &ndash; 52 weeks treatment</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:641px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Once-weekly somapacitan</p><p>(N=132)</p></td><td style="vertical-align:top"><p>Once-daily somatropin</p><p>(N=68)</p></td><td style="vertical-align:top"><p>Estimate of treatment difference (95% CI) (somapacitan minus somatropin)</p></td></tr><tr><td style="vertical-align:top"><p>Height SDS, baseline<sup>a</sup></p></td><td style="vertical-align:top"><p>-2.99</p></td><td style="vertical-align:top"><p>-3.47</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Height SDS, change from baseline&nbsp;</p></td><td style="vertical-align:top"><p>1.25</p></td><td style="vertical-align:top"><p>1.30</p></td><td style="vertical-align:top"><p>-0.05 [-0.18; 0.08]</p></td></tr><tr><td style="vertical-align:top"><p>IGF-I SDS, baseline<sup>a</sup></p></td><td style="vertical-align:top"><p>-2.03</p></td><td style="vertical-align:top"><p>-2.33</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>IGF-I SDS, week 52<sup>a</sup></p></td><td style="vertical-align:top"><p>0.28</p></td><td style="vertical-align:top"><p>0.10</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>IGF-I SDS level change from baseline</p></td><td style="vertical-align:top"><p>2.36</p></td><td style="vertical-align:top"><p>2.33</p></td><td style="vertical-align:top"><p>0.03 [-0.30; 0.36]</p></td></tr></tbody></table><p><sup>a </sup>Observed mean</p><p>&nbsp;</p><p>The vast majority of paediatric patients (96.9%) in the trial achieved an average IGF-I SDS level within normal range (-2 to +2) after 52 weeks of treatment with once weekly somapacitan (Table 6). A low number of patients had average IGF-I SDS above +2 (2.3%) and no patients had average IGF-I SDS above +3.</p><p>&nbsp;</p><p><strong>Table&nbsp;6: Average IGF-I SDS values after 52 weeks of treatment of paediatric patients with GHD with once weekly somapacitan</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:416px"><tbody><tr><td style="vertical-align:top"><p>IGF-I SDS category</p></td><td style="vertical-align:top"><p>Week 52 average</p><p>(N=132)</p></td></tr><tr><td style="vertical-align:top"><p>&lt;-2</p></td><td style="vertical-align:top"><p>0.8%</p></td></tr><tr><td style="vertical-align:top"><p>-2 to 0</p></td><td style="vertical-align:top"><p>21.2%</p></td></tr><tr><td style="vertical-align:top"><p>0 to +2</p></td><td style="vertical-align:top"><p>75.8%</p></td></tr><tr><td style="vertical-align:top"><p>+2 to +3</p></td><td style="vertical-align:top"><p>2.3%</p></td></tr><tr><td style="vertical-align:top"><p>&gt;+3</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>&nbsp;</p><p><em>REAL 3 (phase 2)</em></p><p>A total of 59 GH treatment-na&iuml;ve GH-deficient paediatric patients completed a 26-week main period and a 26-week extension in a 4-arm parallel group trial with once weekly somapacitan at dose levels of 0.04, 0.08 and 0.16&nbsp;mg/kg/week and active control arm of 0.034&nbsp;mg/kg/day daily somatropin. The patients continued in a 104-week open-label safety extension parallel arms with somapacitan 0.16&nbsp;mg/kg/week and daily somatropin 0.034&nbsp;mg/kg/day. All patients were afterwards transferred to once weekly somapacitan 0.16&nbsp;mg/kg/week in a 208-week long-term safety extension.</p><p>&nbsp;</p><p>Treatment with once weekly somapcitan led to continuous treatment benefits up to at least week 208. Height SDS was -1.06 (change from baseline: 2.85) in 38 patients.</p><p>&nbsp;</p><p>Height outcome obtained at week 208 in patients switching from 0.034&nbsp;mg/kg/day daily somatropin to 0.16&nbsp;mg/kg/week once weekly somapacitan at week 156 indicated that treatment benefits with daily GH treatment are maintained after switching to once weekly somapacitan.</p><p>&nbsp;</p><p>Mean IGF-I SDS remained within the normal range for all groups.</p><p>&nbsp;</p><p><em>Adult GHD</em></p><p>In a 34‑week placebo‑controlled (double-blind) and active‑controlled (open) trial, 301 treatment‑na&iuml;ve adult patients with GHD were randomised (2:1:2) and 300 were exposed to once-weekly somapacitan or to placebo or to daily somatropin<sup> </sup>for a 34‑week treatment period (main phase of the trial). The patient population had a mean age of 45.1&nbsp;years (range 23-77&nbsp;years; 41 patients were 65&nbsp;years or above), 51.7% were females, and 69.7% had adult onset GHD.</p><p>A total of 272 adult GHD patients who completed the 34‑week main phase continued in a 53‑week open‑label extension period. Subjects on placebo were switched to somapacitan and patients on somatropin were re‑randomised (1:1) to either somapacitan or somatropin.</p><p>&nbsp;</p><p>Observed clinical effects for the main endpoints in the main treatment phase (Table <u>7</u>) and extension treatment phase (Table 8) are presented below.</p><p>&nbsp;</p><p><strong>Table 7: </strong><strong>Results at 34&nbsp;weeks </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:601px"><thead><tr><td><p><strong>Change from baseline at 34 weeks<sup>a </sup></strong></p></td><td><p><strong>somapacitan </strong></p></td><td><p><strong>somatropin</strong></p></td><td><p><strong>placebo</strong></p></td><td><p><strong>Difference</strong></p><p><strong>somapacitan -placebo<br />[95% CI]</strong></p><p><strong>p‑value </strong></p></td><td style="vertical-align:top"><p><strong>Difference somapacitan- somatropin<br />[95% CI]</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td><p>Number of subjects (N)</p></td><td><p>120</p></td><td><p>119</p></td><td><p>61</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Truncal fat %</p><p>(Primary endpoint)</p></td><td><p>-1.06</p></td><td><p>-2.23</p></td><td><p>0.47</p></td><td><p>-1.53<br />[-2.68; -0.38]<br />0.0090<sup>b</sup></p></td><td style="vertical-align:top"><p>1.17 [0.23;2.11]</p><p>&nbsp;</p></td></tr><tr><td><p>Visceral adipose tissue (cm<sup>2</sup>)</p></td><td><p>-10</p></td><td style="vertical-align:top"><p>-9</p></td><td><p>3</p></td><td style="vertical-align:top"><p>-14<br />[-21; -7]<br />&nbsp;</p></td><td style="vertical-align:top"><p>-1<br />[-7; 4]<br />&nbsp;</p></td></tr><tr><td><p>Appendicular skeletal muscle mass (g)</p></td><td><p>558</p></td><td style="vertical-align:top"><p>462</p></td><td><p>-121</p></td><td style="vertical-align:top"><p>679<br />[340; 1,019]<br />&nbsp;</p></td><td style="vertical-align:top"><p>96<br />[-182; 374]<br />&nbsp;</p></td></tr><tr><td><p>Lean body mass (g)</p></td><td><p>1,394</p></td><td style="vertical-align:top"><p>1,345</p></td><td><p>250</p></td><td style="vertical-align:top"><p>1144<br />[459; 1,829]<br />&nbsp;</p></td><td style="vertical-align:top"><p>49<br />[-513;610]<br />&nbsp;</p></td></tr><tr><td><p>IGF-I SDS level</p></td><td><p>2.40</p></td><td style="vertical-align:top"><p>2.37</p></td><td><p>-0.01</p></td><td style="vertical-align:top"><p>2.40<br />[2.09; 2.72]<br />&nbsp;</p></td><td style="vertical-align:top"><p>0.02<br />[-0.23;0.28]<br />&nbsp;</p></td></tr></tbody></table><p><strong>Abbreviations: </strong>N = Number of subjects in full analysis set, CI = Confidence interval, DM=Diabetes mellitus. IGF-I SDS: Insulin-like growth factor-I standard deviation score.</p><p><sup>a </sup>Body composition parameters are based on dual-energy X-ray absorptiometry (DXA) scanning.</p><p><sup>b</sup> The primary analysis was a comparison of changes from baseline for somapacitan and placebo in truncal fat %. Changes in truncal fat % from baseline to the 34&nbsp;week&rsquo;s measurements was analysed using an analysis of covariance model with treatment, GHD onset type, sex, region, DM and sex by region by DM interaction as factors and baseline as a covariate incorporating a multiple imputation technique where missing week&nbsp;34 values were imputed based on data from the placebo group.</p><p>&nbsp;</p><p><em>Post-hoc</em> subgroup analysis of changes from baseline in truncal fat percentage (%) compared to placebo at week 34 showed an estimated treatment difference (somapacitan-placebo) of -2.49% [-4.19; -0.79] in men, -0.80% [-2.99; 1.39] in women not on oral oestrogen, -1.44% [-3.97; 1.09] in women on oral oestrogen.</p><p>&nbsp;</p><p><strong>Table 8: </strong><strong>Results at 87</strong><strong>&nbsp;</strong><strong>weeks </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:601px"><thead><tr><td><p><strong>Change from baseline at 87 weeks<sup>a</sup> </strong></p></td><td><p><strong>somapacitan/<br />somapacitan </strong></p></td><td><p><strong>somatropin/<br />somatropin</strong></p></td><td><p><strong>placebo/<br />somapacitan</strong></p></td><td><p><strong>somatropin/<br />somapacitan</strong></p></td><td style="vertical-align:top"><p><strong>Difference somapacitan/<br />somapacitan vs somatropin/somatropin&nbsp;<br />[95% CI]</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td><p>Number of subjects (N)</p></td><td><p>114</p></td><td><p>52</p></td><td><p>54</p></td><td><p>51</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Truncal fat %</p></td><td><p>-1.52</p></td><td style="vertical-align:top"><p>-2.67</p></td><td><p>-2.28</p></td><td><p>-1.35</p></td><td style="vertical-align:top"><p>1.15<br />[-0.10; 2.40]<br />&nbsp;</p></td></tr><tr><td><p>Visceral adipose tissue (cm<sup>2</sup>)</p></td><td><p>-6.64</p></td><td style="vertical-align:top"><p>-6.85</p></td><td><p>-10.21</p></td><td><p>-8.77</p></td><td style="vertical-align:top"><p>0.22</p><p>[-10; 10]<br />&nbsp;</p></td></tr><tr><td><p>Appendicular skeletal muscle mass (g)</p></td><td><p>546.11</p></td><td><p>449.09</p></td><td><p>411.05</p></td><td><p>575.80</p></td><td style="vertical-align:top"><p>97.02<br />[-362; 556]<br />&nbsp;</p></td></tr><tr><td><p>Lean body mass (g)</p></td><td><p>1,739.05</p></td><td style="vertical-align:top"><p>1,305.73</p></td><td><p>1,660.56</p></td><td style="vertical-align:top"><p>1,707.82</p></td><td style="vertical-align:top"><p>433.32<br />[-404; 1271]<br />&nbsp;</p></td></tr></tbody></table><p><sup>a</sup> Body composition parameters are based on DXA scanning.</p><p>&nbsp;</p><p><em>Observed and simulated IGF-I SDS levels in the clinical study</em></p><p>In the main phase of the clinical study IGF-I SDS values of 0 and above were overall achieved in 53% of somapacitan-treated adult GHD study patients after an 8-week dose titration period. This proportion was however lower in particular subgroups such as women on oral oestrogen (32%) and patients with childhood-onset (39%) (Table 9). <em>Post-hoc</em> simulation analyses indicated that the proportions of adult GHD patients achieving IGF-I SDS levels above 0 are expected to be higher in case somapacitan dose titration beyond 8&nbsp;weeks would be allowed. In this simulation analysis, it was assumed that somapacitan dose titration was well-tolerated in all patients until the IGF-I SDS target range or a somapacitan dose of 8&nbsp;mg per week would be achieved.</p><p>&nbsp;</p><p><strong>Table 9 Proportions of somapacitan-treated adult GHD patients with IGF-I SDS levels above 0</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong><u>Subgroups</u></strong></p></td><td><p><strong>Men</strong></p></td><td><p><strong>Women not on oral oestrogen</strong></p></td><td><p><strong>Women on oral oestrogen</strong></p></td><td><p><strong>Childhood-onset adult GHD</strong></p></td><td><p><strong>Adult-onset adult GHD</strong></p></td><td><p><strong>All</strong></p></td></tr><tr><td><p>Observed<sup>a</sup></p></td><td><p>71%</p></td><td><p>46%</p></td><td><p>32%</p></td><td><p>39%</p></td><td><p>60%</p></td><td><p>53%</p></td></tr><tr><td><p><em>Post-hoc</em> simulations</p></td><td><p>100%</p></td><td><p>96%</p></td><td><p>70%</p></td><td><p>84%</p></td><td><p>92%</p></td><td><p>90%</p></td></tr></tbody></table><p><sup>a</sup> The trial was designed to titrate towards a IGF-I SDS level above -0.5</p><p>&nbsp;</p><p><em>Maintenance dose</em></p><p>Maintenance dose varies from person to person and between male and female patients. The average somapacitan maintenance dose observed in the phase 3 clinical trials was 2.4&nbsp;mg/week.</p><p>&nbsp;</p><p><em>Paediatric and adult GHD</em></p><p><em>Clinical safety</em></p><p>The safety profile of somapacitan was similar to the well-known safety profile of somatropin. No new safety issues were identified,see section 4.8.</p><p><em>&nbsp;</em></p><p><em>Immunogenicity </em></p><p>Anti-drug antibodies (ADA) were uncommonly detected in peadiatric patients (16/132). None of these antibodies were neutralising. No evidence of ADA impact on pharmacokinetics, efficacy or safety was observed. No anti-drug antibodies were detected in adult patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Somapacitan has pharmacokinetic properties compatible with once weekly administration. The reversible binding to endogenous albumin delays elimination of somapacitan and thereby prolongs the <em>in vivo</em> half‑life and duration of action.</p><p>&nbsp;</p><p>The pharmacokinetics of somapacitan following subcutaneous administration have been investigated at dose levels from 0.02&nbsp;to 0.16&nbsp;mg/kg/week in paediatric population (2.5 to 14 years), at dose levels from 0.01&nbsp;to 0.32&nbsp;mg/kg in healthy adults, and in doses up to 0.12&nbsp;mg/kg in patients with adult GHD.</p><p>&nbsp;</p><p>Overall, somapacitan displays non-linear pharmacokinetics, <s>but</s> across the investigated dose range. However, in the clinically relevant dose range of somapacitan in adults GHD, somapacitan pharmacokinetics are approximately linear.</p><p>In paediatric GHD, a somapacitan dose of 0.16&nbsp;mg/kg/week corresponds to an average concentration of 80.2&nbsp;ng/mL and in adult GHD, somapacitan doses in the clinically relevant range correspond to average concentrations of 0.1-36.2&nbsp;ng/mL.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>In adult and paediatric patients with GHD median t<sub>max</sub> ranged from 4 to 25.5 hours at doses from 0.02&nbsp;mg/kg/week to 0.16&nbsp;mg/kg/week.</p><p>Steady state exposure was achieved following 1‑2&nbsp;weekly administration.</p><p>Absolute bioavailability of somapacitan in humans has not been investigated.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Somapacitan is extensively bound (&gt;99%) to plasma proteins and is expected to be distributed like albumin. Based on population PK analyses, the estimated volume of distribution (V/F) was 1.7 L in paediatric GHD patients and 14.6&nbsp;L in adult GHD patients.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>&nbsp;</p><p>Following a single dose and repeated dosing of 0.16&nbsp;mg/kg/week the terminal half-life was approximately 34 hours in paediatric GHD patients.</p><p>The terminal half‑life was estimated with geometric means ranging from approximately 2 to 3&nbsp;days at steady state in paediatric and adult GHD patients (doses: 0.02 to 0.12&nbsp;mg/kg).</p><p>Somapacitan will be present in circulation for approximately 2&nbsp;weeks after the last dose. Little to no accumulation (mean accumulation ratio: 1‑2) of somapacitan following multiple dosing has been observed.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Somapacitan is extensively metabolised by proteolytic degradation and cleavage of the linker sequence between the peptide and albumin binder.</p><p>&nbsp;</p><p>Somapacitan was extensively metabolised before excretion and no intact somapacitan was found neither in urine, which was the main excretion route (81%), nor in faeces where 13% of somapacitan related material was found, indicating full biotransformation before excretion.</p><p>&nbsp;</p><p><u>Special population</u><u>s</u></p><p><em>&nbsp;</em></p><p><em>Paediatric GHD patients</em></p><p>Based on population pharmacokinetic analysis gender, race and body weight do not have a clinically meaningful effect on the pharmacokinetics following weight-based dosing.</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Adult GHD patients</em></p><p><em>Age</em></p><p>Subjects older than 60&nbsp;years have higher exposure (29%) than younger subjects at the same somapacitan dose. A lower starting dose for subjects above 60&nbsp;years is described in section 4.2.</p><p>&nbsp;</p><p><em>Gender </em></p><p>Female subjects and in particular female subjects on oral oestrogen, have lower exposure (53% for females on oral oestrogen and 30 % for females not on oral oestrogen) than male subjects at the same somapacitan dose. A higher starting dose for females on oral oestrogen is described in section 4.2.</p><p>&nbsp;</p><p><em>Race </em></p><p>There was no difference in somapacitan exposure and IGF‑I response between Japanese and White subjects. Despite a higher exposure in Asian Non-Japanese compared to White at the same somapacitan dose, White, Japanese and Asian Non-Japanese needed the same doses to reach similar IGF‑I levels. Therefore, there is no dose adjustment recommendation based on race.</p><p><em><u>&nbsp;</u></em></p><p><em>Ethnicity</em></p><p>Ethnicity (Hispanic or Latino 4.5% (15 subjects received somapacitan)) was not investigated due to small sample size in the development programme.</p><p><em>&nbsp;</em></p><p><em>Body weight</em></p><p>Despite a higher exposure in subjects with low body weight as compared to subjects with high body weight at the same somapacitan dose, subjects needed the same doses to reach similar IGF‑I levels across the body weight range 35&nbsp;kg to 150&nbsp;kg. Therefore, there is no dose adjustment recommendation based on body weight.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>A somapacitan dose of 0.08&nbsp;mg/kg at steady state resulted in higher exposures in subjects with renal impairment, most pronounced in subjects with severe renal impairment and in subjects requiring haemodialysis, where AUC&nbsp;<sub>0-168h</sub> ratios to normal renal function were 1.75 and 1.63, respectively. In general, somapacitan exposure tended to increase with decreasing GFR.</p><p>Higher IGF‑I&nbsp;<sub>AUC0-168h</sub> levels were observed in subjects with moderate and severe renal impairment and subjects requiring haemodialysis, with ratios to normal renal function of 1.35, 1.40 and 1.24 respectively.</p><p>Due to the modest increase observed in IGF‑I combined with the low recommended starting doses and the individual dose titration of somapacitan, there is no dose adjustment recommendation in patients with renal impairment.</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>A somapacitan dose of 0.08&nbsp;mg/kg at steady state resulted in higher exposure in subjects with moderate hepatic impairment with ratios to normal hepatic function of 4.69 for AUC<sub>0-168h</sub> and 3.52 for C<sub>max</sub>.</p><p>Lower somapacitan stimulated IGF‑I levels were observed in subjects with mild and moderate hepatic impairment compared to subjects with normal hepatic function (ratio to normal was 0.85 for mild and 0.75 for moderate).</p><p>Due to the modest decrease observed in IGF‑I combined with the individual dose titration of somapacitan, there is no dose adjustment recommendation in patients with hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, genotoxicity or pre- and postnatal development.</p><p>&nbsp;</p><p>No carcinogenicity studies have been performed with somapacitan.</p><p>&nbsp;</p><p>No adverse effects were observed on male and female fertility in rats at a dose resulting in exposure at least 13 and 15‑times greater than the expected maximum clinical exposure at 8&nbsp;mg/week for males and females, respectively. However, irregular female oestrus cycle was seen at all doses treated.</p><p>&nbsp;</p><p>No evidence of foetal harm was identified when pregnant rats and rabbits were administered subcutaneous somapacitan during organogenesis at doses leading to exposures well above expected exposure at the maximum clinical dose of 8&nbsp;mg/week (at least 18‑fold). At high doses leading to exposure at least 130-fold above the expected maximum clinical exposure at 8&nbsp;mg/week, short/bent/thickened long bones were found in pups from female rats receiving somapacitan. Such findings in rats are known to resolve after birth and should be regarded as minor malformations, not permanent abnormalities.</p><p>Foetal growth was reduced when pregnant rabbits were dosed with somapacitan subcutaneously at exposures at least 9-fold above the expected exposure at the maximum clinical dose of 8&nbsp;mg/week.</p><p>&nbsp;</p><p>In lactating rats, somapacitan related material was secreted into milk but to a lower level than observed in plasma (up to 50% of level in plasma).</p><p><u>&nbsp;</u></p><p>Preclinical data on distribution</p><p>&nbsp;</p><p>Somapacitan distributes to the hypertrophic zone and primary spongiosa in the epiphysis of proximal tibia of GH‐deficient hypophysectomised rats. Distribution of somapacitan to peripheral tissues is comparable to GH.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Histidine</p><p>Mannitol</p><p>Poloxamer&nbsp;188</p><p>Phenol</p><p>Water for injections</p><p>Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pH adjustment).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Expiry date is stated on the pen label and carton after ’Expiry’.

After first opening 
6 weeks. Store in a refrigerator (2°C - 8°C).
Do not freeze. Keep away from the freezing element.
Keep Sogroya® in the outer carton with the pen cap on to protect from light.

Before and after first opening
If refrigeration is not possible (e.g. during travelling), Sogroya® may be kept temporarily at temperatures up to 30°C for up to a total of 72 hours (3 days). Return Sogroya® to the refrigerator again after storage at this temperature. If stored out of refrigeration and then returned to refrigeration, the total combined time out of refrigeration should not exceed 3 days, monitor this carefully. The Sogroya® pen should be discarded, if it has been kept up to 30°C for more than 72 hours (3 days) or for any period of time kept above 30°C.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze. Keep away from the freezing element.</p><p>Keep Sogroya<sup>&reg;</sup> in the outer carton with the pen cap on to protect from light.</p><p>&nbsp;</p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pre-filled pen consists of 1.5&nbsp;mL solution in a glass cartridge (Type I colourless glass) with a plunger made of chlorobutyl rubber and a stopper made of bromobutyl/isoprene rubber sealed with an aluminium cap. The cartridge is contained in a multidose disposable pen made of polypropylene, polyacetal, polycarbonate and acrylonitrile butadiene styrene and in addition two metal springs. The cartridge is permanently sealed in a pre-filled pen.</p><p>&nbsp;</p><p>Sogroya<sup>&reg;</sup> 5 mg/1.5 mL is a colour-coded pre-filled pen with the dose button on the pen coloured teal.</p><p>&nbsp;</p><p>Pack size of 1 pre-filled pen.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>The pen is for use by one person only.</p><p>&nbsp;</p><p>Sogroya<sup>&reg;</sup> should not be used if the solution does not appear clear to slightly opalescent, colourless to slightly yellow and free from visible particles.</p><p>&nbsp;</p><p>Sogroya<sup>&reg;</sup> must not be used if it has been frozen.</p><p>&nbsp;</p><p>The cartridge must not be taken out of the pre-filled pen and refilled.</p><p>&nbsp;</p><p>A needle must always be attached before use. Needles must not be re-used. The injection needle should be removed after each injection and the pen should be stored without a needle attached. This may prevent blocked needles, contamination, infection, leakage of solution and inaccurate dosing.</p><p>In the event of blocked needles, patients must follow the instructions described in the instructions for use accompanying the package leaflet.</p><p>&nbsp;</p><p>Sogroya<sup>&reg;</sup> can be administered with a needle up to a length of 8 mm. The pen is designed to be used with NovoFine<sup>&reg;</sup> or NovoTwist<sup>&reg;</sup> disposable needles. The needles are not included in the carton.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S 
Novo Allé
DK-2880 Bagsværd
Denmark


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	July-2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>